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ABSTRACT
Bronchiectasis, conventionally deﬁned as irreversible
dilatation of the bronchial tree, is generally suspected
on a clinical basis and conﬁrmed by means of chest
high-resolution computed tomography. Clinical mani-
festations, including chronic productive cough and
endobronchial suppuration with persistent chest infec-
tion and inﬂammation, may deeply affect quality of life,
both in children/adolescents and adults. Despite many
cases being idiopathic or post-infectious, a number of
speciﬁc aetiologies have been traditionally associated
with bronchiectasis, such as cystic ﬁbrosis (CF), pri-
mary ciliary dyskinesia or immunodeﬁciencies. Never-
theless, bronchiectasis may also develop in patients
with bronchial asthma; chronic obstructive pulmonary
disease; and, less commonly, rheumatological disorders
and inﬂammatory bowel diseases. Available literature
on the development of bronchiectasis in these condi-
tions and on its management is limited, particularly in
children. However, bronchiectasis may complicate the
clinical course of the underlying condition at any age,
and appropriate management requires an integration of
multiple skills in a team of complementary experts to
provide the most appropriate care to affected children
and adolescents. The present review aims at summariz-
ing the current knowledge and available evidence on
the management of bronchiectasis in the other condi-
tions mentioned and focuses on the new therapeutic
strategies that are emerging as promising tools for
improving patients’ quality of life.
Key words: asthma, bronchiectasis, chronic obstructive pul-
monary disease, inﬂammatory bowel disease, rheumatological
disease.
INTRODUCTION
Bronchiectasis is a pathological or radiological entity
characterized by irreversible bronchial dilatation with
clinical manifestations that include chronic cough, spu-
tum production and frequent infectious exacerba-
tions.1,2 As such, bronchiectasis represents a
heterogeneous compilation of aetiologies with an
equally protean set of clinical manifestations and
symptoms. These presentations have been character-
ized more recently by a wide range of phenotypes and
endotypes.3,4
High-resolution computed tomography (HRCT) rep-
resents the gold standard for diagnosis both in children
and adults, and despite existing controversies in diag-
nostic criteria for affected children, some key radiologi-
cal features are commonly accepted for deﬁnition.
These are mainly represented by an increased
bronchoarterial ratio, bronchial wall thickening, lack of
bronchial tapering from central to periphery and
mucous plugging.5
Despite generally being considered irreversible, com-
puted tomography (CT)-based studies suggest that
early cylindrical bronchiectasis can potentially revert in
children.6
Historically, and in most recently published series,
the majority of clinical bronchiectasis has been linked
aetiologically to either idiopathic or post-infectious
causes. There are, however, speciﬁc aetiologies associ-
ated with bronchiectasis that include, but are not lim-
ited to, CF, primary ciliary dyskinesia, allergic
bronchopulmonary aspergillosis (ABPA), alpha-
1-antitrypsin deﬁciency, aspiration, immunodeﬁciency,
asthma (non-ABPA), chronic obstructive pulmonary
disease (COPD), rheumatological disease (RD) and
inﬂammatory bowel disease (IBD).2,7 With the excep-
tion of CF-associated bronchiectasis, the heterogeneity
of presentations and natural disease courses implicit to
bronchiectasis has likely contributed to the observed
varied clinical responses to therapeutic interventions,
including results from the recent phase III inhaled anti-
biotic clinical studies that have consistently not met the
primary endpoints.8–11 The extent to which the various
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bronchiectatic phenotypes and endotypes respond to
speciﬁc treatment is essentially unknown and is a mat-
ter of intense research interest and investigation. This
is particularly true for affected children as studies char-
acterizing large paediatric cohorts of bronchiectasis
sharing the same aetiology are limited, making this a
research priority in this ﬁeld.
It is the limited purpose of this study to review the
current available rationale of the speciﬁc management
of bronchiectasis in association with other airways dis-
eases, including COPD and asthma, as well as RD and
IBD in children and adults. Speciﬁc Management of
bronchiectasis has been recently addressed in interna-
tional guidelines.12,13
BRONCHIECTASIS AND COEXISTING
ASTHMA AND COPD IN CHILDREN
As many disorders characterized by recurrent-to-
persistent bronchial injury may eventually result in the
development of bronchiectasis, multiple causes of pae-
diatric bronchiectasis have been reported.14 Regretta-
bly, limited access to diagnostic technology in some
areas, especially in developing countries, makes a pre-
cise assessment of aetiology still poorly deﬁned, and
therefore, even a detailed diagnostic work-up may be
inconclusive in up to 50% of patients.15–18 Nevertheless,
identifying aetiology is very relevant as it can inﬂuence
patients’ management, including investigations for spe-
ciﬁc causes, disease severity evaluation and referral to
specialized centres for the longitudinal follow-up and
start of treatment.
Among the possible causes of bronchiectasis, asthma
should always be ruled out given the high prevalence
of both atopic and non-atopic diseases within the pae-
diatric population. In asthma, major structural abnor-
malities consist of thickening of the conducting airways
with luminal narrowing and excessive mucous produc-
tion associated with inﬂammatory exudates, and these
changes are very relevant, especially in patients with
uncontrolled or severe asthma.19 Thick and/or purulent
secretions can cause progressive obstruction and bron-
chial wall damage that are supposed to be the major
determinants of bronchial dilatation,20 but an addi-
tional mechanism leading to the development of seg-
mental atelectasis with increased negative intrapleural
pressure, progressive traction on bronchial walls, and,
in turn, bronchial dilation should also be considered.21
Bronchial mucous plugging associated with the dilata-
tion of bronchial mucosal blood vessels, congestion
and wall oedema are also consistently reported features
of fatal asthma in young patients,22 but the reasons
why bronchiectasis develops in some but not all chil-
dren with asthma is still unclear. A study from Korea
concluded that patients with asthma and evidence of
bronchiectasis should be monitored carefully because
of the increased number of exacerbations and greater
use of systemic steroids, but this population did not
include children or adolescents.23,24 Undoubtedly, chil-
dren with poor asthma control have an increased risk
of severe exacerbations and progressive loss of lung
function, and bronchial wall thickening on HRCT may
constitute an additional criterion of asthma severity in
this subset of patients.25 Nevertheless, although a rela-
tionship between reticular basement membrane thick-
ness and bronchial wall thickness on HRCT was found
in adults with asthma, this relationship does not appear
to hold true in children with severe uncontrolled
asthma26; thus, there is poor evidence to recommend
the routine use of HRCT in children with severe
asthma unless other causes of bronchiectasis errone-
ously attributed to asthma are excluded.27
Among smoking adults, COPD is extremely common
over 40 years of age and represents a major worldwide
public health concern. In adults, COPD is frequently
associated with bronchiectasis, and patients actually
constitute a subgroup with more severe disease and
more frequent asthma exacerbations. Although COPD
is not included among the chronic pulmonary disor-
ders traditionally described in children or adolescents,
the term chronic obstructive pulmonary disease in chil-
dren has been coined to indicate a cluster of disorders
unrelated to active long-term smoking that may result
in progressive lung structure derangements and persis-
tent airﬂow limitation in adult life.28 Notably, there is
increasing evidence that most adult chronic obstructive
lung diseases have at least part of their origins in early
life, with individuals entering adulthood with incom-
plete lung growth being at increased risk of COPD,
even in the absence of rapid lung function decline.29
The asthma–COPD overlap syndrome (ACOS), with
persistent airﬂow limitation and several features usually
associated either with asthma or with COPD, has also
gained interest in paediatrics.30 As the ACOS may also
include bronchiectasis in the bronchiectasis-associated
subgroup (BCOS), there is increasing evidence that
bronchiectasis may also complicate asthma in children
or adolescents with persistent impaired lung function,
thus conﬁrming that ACOS may develop at younger
ages as well.31,32
Children with uncontrolled asthma require high-
dose inhaled corticosteroids (ICS) in association with a
long-acting β2-agonist (LABA) plus oral leukotriene
receptor antagonist or additional strategies, particularly
anti-IgE treatment.33 There are no trials of ICS in chil-
dren or adolescents with non-CF, bronchiectasis-
associated asthma or COPD, and the existing adult
studies show minimal and, in most cases, no clinically
signiﬁcant beneﬁts.34 The recent European Respiratory
Society (ERS) guidelines for the management of adult
bronchiectasis concluded that ICS do not have a role in
the routine management of adult bronchiectasis12 but
also that, in the absence of speciﬁc data, the presence
of bronchiectasis alone should not lead to a decision to
withdraw ICS from patients with established asthma.
Randomized controlled trials of ICS in children with
bronchiectasis who are naïve to ICS are recommended
to deﬁne the true utility of this therapy.
BRONCHIECTASIS AND COEXISTING
ASTHMA AND COPD IN ADULTS
Perhaps the murkiest assignment of association of
adult bronchiectasis with coexisting diseases is the con-
nection with other airways diseases, including asthma
and COPD.35 In particular, 4–72% of patients with
© 2019 Asian Paciﬁc Society of Respirology Respirology (2019)
2 M Maglione et al.
severe COPD have been recently reported to have
bronchiectasis on CT, with similar frequencies
(20–30%) reported in cohorts with severe or uncon-
trolled asthma.36 For the purposes of this review, ABPA
will be considered a distinct and separate entity aside
from asthma and will not be further discussed. As
described above, the classiﬁcation between different
airway diseases can often represent a semantic and
diagnostic dilemma. The relatively high prevalence of
asthma and COPD in adult populations underscores
the importance of clarifying the need for proper classi-
ﬁcations. Standard deﬁnitions for adults with a diagno-
sis of asthma or COPD have been proposed by global
initiative statements.37 More recently, interest in the
deﬁnition of the ACOS has been increasingly explored,
with many caveats and unknowns still present.38,39 To a
large extent, the importance of deﬁnition becomes as
much as an endotype distinction as it does a pheno-
type distinction.40–42 The ACOS proﬁle has carried with
it a negative impact on the natural course of disease.43
These distinctions have an additional important impact
on the approach to treatment, which has also been
increasingly addressed recently. Many have advocated
for adhering to the treatment of asthma plus COPD
strategies rather than either alone for those individuals
who can be classiﬁed as ACOS.
Most series of primary adult bronchiectasis patients
include a diagnosis of COPD and/or asthma widely
varying in numbers. Characteristic inﬂammatory pro-
ﬁles of bronchiectasis, to a large extent, will not sur-
prisingly overlap with COPD and, in some instances,
asthma as well as the ACOS.44 The rate of COPD as an
accompanying diagnosis to a primary diagnosis of
bronchiectasis is often higher than that of asthma. In a
recent series of European bronchiectasis patients as
part of the FRIENDS cohort, asthma was reported in
3% and COPD in 15%.7 Previous series have reported
numbers as high as 27% of bronchiectasis patients in
Hong Kong.45 In contrast, data taken from the US Reg-
istry estimated that 29% and 20% of patients with bron-
chiectasis enrolled in the US Bronchiectasis and NTM
Research Registry had asthma and COPD, respec-
tively.46 From a different perspective, the numbers of
adult asthma and COPD patients with bronchiectasis
tend to be much higher, especially with advanced
severity of disease. It has been estimated that between
8% and 59% of COPD patients and between 12% and
68% of asthma patients have bronchiectasis of varying
degrees.12,35
Part of the dilemma for clinicians, as well as clini-
cal investigators, is to discern whether one, two or
three diagnoses (bronchiectasis, asthma and/or
COPD) are present. Moreover, it may be equally
challenging to classify bronchiectasis with asthma or
COPD as overlap patients versus asthma and COPD
with bronchiectasis. Being a structural lesion, bron-
chiectasis is deﬁned by relatively strict radiological
diagnostic criteria, such as the ratio of the diameters
of bronchial lumen and adjacent artery. Neverthe-
less, it has been argued that, particularly in smokers,
interpretation of this parameter should be careful as
it might be sensitive to changes in pulmonary arter-
ies.47 The implication of course is to understand
whether speciﬁc therapies directed towards asthma,
COPD or bronchiectasis are applicable. No more
therapeutic intervention illustrates this more poi-
gnantly as ICS. In fact, there is little direct evidence
to support the use of ICS in adult bronchiectasis
patients, and ICS are not recommended other than
when indicated for reasons of asthma or, in some
instances, for COPD as standard of care.12 This need
for reconciliation of ICS use is borne out of observ-
ing that 39% of bronchiectasis patients in the US
Registry are using ICS.46 Furthermore, the relative
use of non-pharmacological, as well as other phar-
macological, therapies is equally unclear, including
mucolytic therapies such as nebulized hypertonic
saline, N-acetyl cysteine, inhaled mannitol and long-
acting bronchodilators including LABA and long-
acting muscarinic agonists (LAMA). Macrolide use in
adult bronchiectasis patients with coexisting COPD
or asthma represents an even larger dilemma. Even
though macrolides have been shown to be effective
in (non-CF) bronchiectasis48–50 and are rec-
ommended for select frequent exacerbator
populations,12 the beneﬁcial use of macrolides in
adult COPD patients and, to even a lesser extent, in
asthma patients is less clear.51–54
There are little data available addressing best thera-
peutic strategies in adult bronchiectasis overlap
patients with coexisting asthma and/or COPD. Further
investigations are sorely needed. In the interim, clini-
cians are probably best served to unbundle speciﬁc
classiﬁcations with reliance on endotype and treatable
traits tied to bronchiectasis to determine the best treat-
ment on a case-by-case basis.55 In an approach to the
individual patient, a concept begins to emerge charac-
terized recently with a label of precision medicine.56
The clinical investigator, on the other hand, during
clinical trial design in the future is charged with an
imperative to a priori address the inevitable issues of
heterogeneity of endotype, phenotype and treatable
traits of adult bronchiectasis patients with or without
coexisting asthma and COPD to make meaningful
observations.
In summary, what is the best approach to the treat-
ment of adult bronchiectasis patients with coexisting
asthma and COPD? It is our opinion that one must
carefully assess the phenotype, endotype and treatable
traits on an individualized basis to best achieve an
individualized therapeutic programme through preci-
sion medicine. As one example, an adult patient with
bronchiectasis and established symptomatic moderate
to severe asthma, including productive cough with
mucous plugging noted on chest imaging, would be a
candidate for asthma triple therapy with LABA, LAMA
and ICS, as well as airway clearance programmes
including trials of hypertonic saline and non-
pharmacological therapies as recommended for bron-
chiectasis patients in accepted guidelines. Likewise, if
frequent exacerbations with or without Pseudomonas
are noted, considerations of additional intervention
according to guideline recommendations may be appli-
cable despite the lack of data to support this speciﬁc
cohort of overlap patients.12 Incorporating endotype
and treatable traits in a treatment programme would
be equally applicable for adult bronchiectasis patients
with coexisting COPD.35
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Future investigations and research are needed to
speciﬁcally address the impact of the integration of
phenotype, endotype and treatable traits in adult bron-
chiectasis patients with coexisting asthma and COPD if
advancing the science of bronchiectasis and closing
knowledge gaps are to occur.
BRONCHIECTASIS AND COEXISTING
RD IN CHILDREN
Pulmonary involvement is frequently reported in pae-
diatric RD, a heterogeneous group of systemic inﬂam-
matory diseases of autoimmune origin that include
juvenile rheumatoid arthritis (RA), polymyositis, sys-
temic lupus erythematosus, scleroderma, dermatomyo-
sitis, Sjogren’s syndrome, Wegener’s granulomatosis
and systemic vasculitis.57
Clinical respiratory manifestations of RD generally
begin with an infectious event that triggers the activa-
tion of the inﬂammatory cascade, eventually resulting
in lung tissue repair with ﬁbroblasts and collagen
deposition. The histopathology of the lung mainly
includes features of interstitial disease with associated
vascular abnormalities and development of ﬁbrosis,
even though the frequency of these ﬁndings is
extremely variable depending on the speciﬁc underly-
ing RD. In addition to this, as in some RDs conducting
airways are involved, bronchiectasis may develop, and
then the association between the two conditions
should be taken into account in the management of
affected patients.
Most of the literature on RD-associated bronchiecta-
sis includes adult studies, and only few anecdotal
reports or small case series include children or adoles-
cents. This severely restricts the literature search on
this issue. The association between bronchiectasis and
RD is best described with juvenile RA. The prevalence
of bronchiectasis in juvenile RA varies considerably in
studies, with a prevalence up to 70% in adulthood and
signiﬁcantly fewer cases among the paediatric popula-
tion, even though the absence of speciﬁc recommenda-
tions on the frequency of chest CT in these patients
likely means that a number of asymptomatic patients
remain undiagnosed.57 Of relevance is the observation
that, in most cases, respiratory symptoms start during
childhood or adolescence and frankly precede the ﬁrst
clinical appearance of arthritis.58 In most cases, mixed
functional obstructive and restrictive impairment (the
latter due to overt interstitial lung disease) may
develop, and at that stage, chronic respiratory insufﬁ-
ciency is prominent.59 Most of the authors agree that,
in juvenile RA, the primum movens is the inﬂamma-
tion that persistently damages the bronchial wall and
then, combined with interstitial ﬁbrosis, forces the
bronchi to become dilated, leading to traction bronchi-
ectasis.60 Dilated bronchi may host respiratory patho-
gens, and recurrent or permanent local infection also
related to secondary immunosuppression results in
bronchial suppuration. A study of adults with RA not
including children or adolescents demonstrated that
bronchiectasis is an unusual but potent model for the
induction of autoimmunity by bacterial infection in the
lung, thus suggesting that the prognosis of the disease
may be worse when bronchiectasis develops.61
Paediatric RD other than juvenile RA is less fre-
quently associated with bronchiectasis and includes
scleroderma, Sjogren’s syndrome, polymyositis and
vasculitis. In affected patients, traction bronchiectasis is
described, but again, paediatric cases are signiﬁcantly
less reported than adults.62 A recent study of
granulomatosis with polyangiitis (Wegener’s) or micro-
scopic polyangiitis not including children or adoles-
cents found that bronchiectasis, documented in 38% of
the cases, did not worsen patients’ outcome when anti-
myeloperoxidase anti-neutrophil cytoplasm antibody-
associated vasculitis was expressed.63 Overall, when
bronchiectasis is documented in association with RD,
the outcome of the underlying disorder seems to be
worse than without RD.57 In addition to this, the
immune dysregulation due to immunosuppressive
drugs likely results in more infectious complications,
namely, recurrent pneumonia, and this signiﬁcantly
increases the risk of developing bronchiectasis. It has
also been postulated that, in adults with autoimmunity
disorders such as polymyositis, respiratory pathogens
may induce autoimmunity and/or exacerbate the dis-
ease, and bronchiectasis may eventually develop.64
BRONCHIECTASIS AND COEXISTING
RD IN ADULTS
RD and bronchiectasis are no less confounding in adults
than children, although as noted above, there are
more data available. Of the connective tissues diseases,
including RA, Sjogren’s syndrome, scleroderma, poly-
myositis/dermatomyositis, systemic lupus erythematosus
and mixed connective tissue disease, interstitial lung dis-
ease is the most common pulmonary manifestation.65
Traction bronchiectasis associated with the interstitial
disease will not be a focus of this discussion, although, if
present and if clinical features resemble that of primary
bronchiectasis, general recommendations may be
applied as have been suggested by international guide-
lines.12 It is interesting that, as mentioned above, the sys-
temic inﬂammatory responses of RA and responses
associated with speciﬁc airway infections in bronchiecta-
sis may predispose to the development of bronchiectasis
and RA, respectively.66,67
The occurrence of RA with bronchiectasis is gener-
ally lower than the association with COPD. In a recent
series from six different European centre cohorts of
bronchiectasis, 1–23% of patients also carried a diagno-
sis of RA,66 which is not dissimilar to the 8% of bronchi-
ectasis patients also having RD in the US registry.46
Others have estimated the prevalence to be between
3% and 5.2%15,68 with the exception being a rate of
28.6% in a US urban cohort of African-Americans.69
The presence of any bronchiectasis, including by
HRCT, is otherwise common in RA patients and is esti-
mated to be between 3% and 62% as reported by a
number of series of patients.67 Interestingly, a lower
incidence appeared to be unique for Chinese patients.70
The demographics and severity based on the Bronchi-
ectasis Severity Index (BSI) in the European cohorts of
bronchiectasis with RA were similar to those
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bronchiectasis patients without RA or other causes of
bronchiectasis other than COPD. The bronchiectasis
COPD cohort in this same European series had more
Pseudomonas infection, male predominance, lower
forced expiratory volume in 1 s (FEV1) and higher BSI
scores. Moreover, the overall 5-year mortality in com-
parison between bronchiectasis, bronchiectasis with RA
and bronchiectasis with COPD increased from 8.6% to
18% to 28.5%, respectively.66 The increased mortality
associated with the presence of RA in bronchiectasis
patients extended across all BSI scores. For compari-
son, increased 5-year mortality was seen in RA–
interstitial lung disease patients (63.4%) compared to
RA–bronchiectasis (12.9%) in a separate series.71
Disease-modifying anti-rheumatic drugs (DMARD)
including biologic and non-biologic agents are com-
monly used in RA patients. No changes in DMARD use
were seen in RA patients with or without bronchiecta-
sis.66 Although many of the biologic and non-biologic
DMARD can increase the risk of infection and, in some
instances (e.g. methotrexate or biologic), have well-
described potential pulmonary side effects from the
medication itself, there is no clear predisposition of
DMARD being independently associated with develop-
ing bronchiectasis.67
Treatment implications dictate that adult bronchiec-
tasis patients with coexisting RA are best cared for by a
collaboration of pulmonary physician as well as rheu-
matologist. There appears to be no speciﬁc therapies
for bronchiectasis patients based on the presence or
absence of RA. Nonetheless, the use of many of the
biologic and non-biologic agents needed attention and
precautions, including Pneumocystis jirovecii pneumo-
nia (PJP) prophylaxis, as well as screening for non-
tuberculous mycobacteria (NTM) or latent tuberculosis
(TB) infection (LTBI). Moreover, airway clearance
appears to be no less important than in a general adult
bronchiectasis population. For those adult bronchiecta-
sis patients with RA and frequent chest exacerbations,
use of inhaled antibiotics, macrolide or other suppres-
sive antibiotic may be reasonable to consider following
international guidelines.12 Best practice in our opinion
requires ample communication and cooperation
between pulmonary and rheumatology physicians, as
well as other care team members including chest phys-
iotherapists, nurses and pharmacists when involved.
BRONCHIECTASIS AND COEXISTING
IBD IN CHILDREN
IBD, namely Crohn’s disease (CD) and ulcerative colitis
(UC), are chronic disorders primarily affecting the gas-
trointestinal tract and differ in the distribution of
inﬂammatory lesions, histological features and clinical
presentation. IBD pathogenesis likely moves from a
complex interaction between genetic, environmental
and immunoregulatory factors.72 Extra-intestinal mani-
festations are observed in both conditions but are far
more frequent in CD, which can be observed in
approximately 25–40% of affected subjects.73
Given its low prevalence, bronchopulmonary
involvement is seldom considered a potential expres-
sion of IBD, and therefore, it is often overlooked,
particularly in children. Nevertheless, lung involvement
may be reasonably expected due to the structural simi-
larities between gut and bronchial tree and their com-
mon origin from the primitive foregut.72
Despite the reported prevalence of pulmonary manifes-
tations being similar between UC and CD,74 parenchymal
abnormalities and large airway disease seem to be more
commonly associated with UC,75 even though available
data from adult studies and large paediatric populations
have not been investigated for lung involvement.
Non-speciﬁc airway inﬂammation is the most fre-
quent pulmonary manifestation in IBD and may lead to
the development of bronchiolitis obliterans, organizing
pneumonia and bronchiectasis.76 Bronchial hyper-
responsiveness has been considered an expression of
IBD subclinical airway inﬂammation, a phenomenon
that can be responsible for the development of various
pulmonary manifestations, particularly in CD.77
In children with IBD, pulmonary involvement is gen-
erally much more uncommon than in adults78 and has
been more frequently described in CD.79–81 Bronchiec-
tasis has been described in up to 66% of IBD adults
with airway disease, whereas chronic bronchitis and
suppurative large airway disease without airway dila-
tion represent less common manifestations.82 Neverthe-
less, the reported prevalence is deeply affected by
patient selection, as shown by two adult studies that
detected bronchiectasis and other pulmonary abnormal-
ities at chest CT in the majority of the considered sub-
jects, probably due to the presence of respiratory
symptoms within the selection criteria.83 On the other
hand, a paediatric study assessing lung disease by
means of HRCT in 32 IBD subjects with no respiratory
symptoms found mild bronchiectasis only in one child.78
Finally, an interesting aspect that is emerging in IBD
literature is the possibility of treating CD-associated
pulmonary lesions by means of inﬂiximab, the widely
used anti-TNF-α monoclonal antibody approved for
CD treatment about 20 years ago. The few described
cases involve both adults84 and children,85 and struc-
tural abnormalities that proved responsive to inﬂiximab
included bronchiolitis obliterans, organizing pneumo-
nias and non-caseating granulomas.
Early detection of bronchiectasis, as well as of other
associated pulmonary complications, would hopefully
help to start specialized management of the disease
and improve the ﬁnal outcome. The integration of sev-
eral specialists dedicated to airway disease manage-
ment in a multidisciplinary team including paediatric
rheumatologists, gastroenterologists, allergists,
pulmonologists, radiologists and respiratory therapists
is essential to provide the most appropriate care to
affected children and adolescents.
Unfortunately, indications or recommendations spe-
ciﬁcally made for the management of bronchiectasis
associated with IBD are not available as is the case for
coexisting asthma, COPD or RA. The identiﬁcation of
bronchiectasis generally relies on HRCT, a technique
that has signiﬁcantly increased the sensitivity and mon-
itoring of the diagnosis (Fig. 1). Evidence of bronchiec-
tasis requires microbiological surveillance by means of
regular sputum cultures in order to provide prompt
antibiotic treatment of chest infections. In daily prac-
tice, core prescriptions should include airway clearance
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techniques and pulmonary rehabilitation programmes,
as suggested in most guidelines or consensus on adult
or paediatric bronchiectasis.12,86 As patients with bron-
chiectasis suffer from recurrent exacerbations, resulting
in further destruction of the airways and reduced qual-
ity of life, a strategy addressed to reduce the level of
bronchial infection by long-term use of macrolides
might also be proposed to limit the risk of the persis-
tent antigenic stimulation of bacterial infections
increasing the underlying inﬂammatory processes.87 As
only very few studies in children have been published
on this issue, future research is warranted to investigate
the efﬁcacy of macrolides in the paediatric population
with bronchiectasis.88
BRONCHIECTASIS AND COEXISTING
IBD IN ADULTS
In two recent series of adult bronchiectasis patients,
IBD has occurred even less often than the aforemen-
tioned groups of asthma, COPD and RA patients, rang-
ing from 1% to 3% in the European series and 3% in
the US Registry.7,46 Bronchiectasis is comparable in fre-
quency to other pulmonary manifestations in IBD
patients including bronchiolitis with organizing pneu-
monia or chronic bronchitis74 and ranges from 18% to
26%. These pulmonary manifestations in adults have
generally been more commonly described with UC
than with CD and may precede or follow (after years) a
diagnosis of IBD. Interestingly, cases of bronchiectasis
in both UC and CD have been described following
colectomy with full preoperative pulmonary documen-
tation, including clear lung ﬁelds in some.83,89
A special characteristic of the treatment approach
worth highlighting for bronchiectasis and other pulmo-
nary manifestations in IBD patients reﬂects the clinical
improvement, often times marked, due to corticoste-
roids. Clinical experience and early reports have docu-
mented a consistent response to ICS (and systemic
corticosteroids).74 How these improvements correlate
to observations of elevated exhaled nitric oxide known
to be present in some IBD patients remains
unclear.90,91
Moreover, the increase in the use of biologics for the
treatment of IBD compel the clinician to be vigilant
regarding lung health hygiene, updating vaccines and
screening for atypical pathogens as is carried out for
RA patients on biologics, including but not limited to
TB (LTBI) and NTM. Prophylaxis for PJP is no less
important for IBD bronchiectasis patients when immu-
nosuppressive therapies are used.
In any case, the approach to the treatment of adult
bronchiectasis patients follows the aforementioned pat-
tern of a general approach as outlined in international
bronchiectasis guidelines. Special attention is also
given to the role of treating symptomatic IBD bronchi-
ectasis patients with corticosteroids. Other therapies,
including biologics, along with required screening and
monitoring may be needed for the treatment of IBD.92
CONCLUSIONS
Over the past decades, several paediatric disorders
associated with bronchiectasis have been identiﬁed.
For many of these, new therapeutic strategies are cur-
rently available and have improved patients’ life expec-
tation as some offer the potential of a cure.
Improvements in the quality and implementation of
medical care would hopefully result in increased sur-
vival. Bronchiectasis is an important issue for paediat-
ric patients with asthma or RD or IBD. It may
complicate the clinical course at any age, and there-
fore, appropriate care is mandatory after taking into
account the major characteristics of the disease
(Table 1). The optimal integration of multiple skills in a
team, including physicians with proven experience in
the management of the underlying disease, as well as
other complementary specialists, is ideal for improving
the prognosis of associated bronchiectasis disease.
These specialists have an opportunity to play an
Figure 1 High-resolution computed tomography scans showing diffuse bronchiectasis in the lower lobes from (A) a 16-year-old-girl
with atopic moderate-to-severe bronchial asthma and (B) an 18-year-old-girl with polymyositis.
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integrated role in the multidisciplinary approach to the
diseases. Clinical suspicion, early recognition and
prompt diagnosis of bronchiectasis associated with
these challenging disorders are crucial as outcomes of
treatment in many cases appear time-sensitive, with
better results being achieved when intervention is initi-
ated at a younger age or before the diseases has
progressed.
Speciﬁc treatment approaches to the adult patient
with bronchiectasis with coexisting asthma, COPD, RA
and IBD are not dissimilar to the approach to children
with few caveats. More speciﬁcally, patients with bron-
chiectasis with or without coexisting conditions need to
be thoroughly evaluated, monitored regularly and sub-
scribe to general lung health measures as outlined in
international guidelines. Recommendations include the
avoidance of tobacco exposure and air pollution,
update of pneumococcal and inﬂuenza vaccines, for-
mulation of an airway clearance regimen and regular
physical activity with or without formal participation in
pulmonary rehabilitation. Exacerbations should be
treated promptly and completely, with special attention
given to those patients who are frequent exacerbators,
including consideration of nebulized antibiotics, mac-
rolides or other suppressive therapy. Just as in the case
of children, the approach to the adult with bronchiec-
tasis and coexisting disease must be individualized,
goals of treatment must be articulated, and expecta-
tions of risks and beneﬁts mused be clariﬁed in
advance. Heavy reliance on patient education and use
of a multidisciplinary team including nursing, respira-
tory therapy and pharmacy, as well as the respiratory
and other physicians involved, is likely to optimize
treatment success and improve clinical course in our
experience.
Aside from adhering to elements of standardized bron-
chiectasis treatment regimens, the treating respiratory
physician is unequivocally compelled to identify speciﬁc
coexisting conditions warranting consultation with non-
respiratory providers including rheumatologists, allergists,
immunologists and/or gastroenterologists.
Speciﬁc therapies will need to be matched to identify
speciﬁc phenotypes, endotypes and treatable traits in
an individualized manner consistent with precision
medicine. Whether select adult bronchiectasis patients
are candidates for corticosteroids for coexisting asthma
or IBD, biologics for RA or IBD or other speciﬁc thera-
pies remain a dynamic and ongoing process tied
closely not only to the initial evaluation but also to the
results of continued monitoring and additional changes
in clinical status.
The clinical investigator, in contrast, has the most
daunting challenge, and unequalled opportunity,
starting from the position and understanding that most
of the components of treatment programmes for bron-
chiectasis patients with coexisting diseases are based
on little or no data. Moreover, the strength of recom-
mendations is weak, even for those patients without
coexisting conditions as suggested in recent guidelines.
Clinical investigators, in addition, are charged to a
priori deﬁne speciﬁc phenotypes, endotypes and treat-
able traits with respect to enrolment in clinical trials.
Researchers must remain disciplined to not understate
or over-extrapolate the heterogeneity of cohorts of
Table 1 Major structural and clinical characteristics of adult and paediatric bronchiectasis associated with other
coexisting disorders
Asthma and COPD Rheumatological disorders
Inﬂammatory bowel
diseases
Major structural
abnormalities
Thickening of conducting
airways
Excessive mucous production
Inﬂammatory exudates
Dilatation of bronchial
mucosal blood vessels with
congestion and wall oedema
Associated vascular
abnormalities, ﬁbrosis
(variable, depending on the
speciﬁc underlying disease)
Traction bronchiectasis
Diffuse bronchial wall
thickening (with or without
mucoid impaction)
Bronchiectasis (cylindrical,
varicose or cystic)
Implications for clinical
management
Prolonged ICS therapy
provides minimal or no
beneﬁt in the treatment of
associated bronchiectasis
Adults may beneﬁt from
asthma triple therapy
(LABA, LAMA and ICS), as
well as from airway
clearance programmes
In COPD-associated
bronchiectasis, more
Pseudomonas infections and
worse respiratory function
Respiratory symptoms often
start during childhood or
adolescence, before
rheumatological symptoms
Possible induction of
autoimmunity by lung
bacterial infections may
worsen ﬁnal prognosis
when bronchiectasis
develops
Immune dysregulation due to
immunosuppressive drugs
results in more infectious
complications, thus
increasing the risk of
bronchiectasis
Pulmonary involvement less
common in children than in
adults, more frequently in
CD than UC
Microbiological surveillance
needed for prompt
treatment of chest infections
Bronchiectasis in both UC and
CD may follow colectomy
even in the absence of
preoperative lung
impairment
Increased susceptibility to
opportunist infections due to
immunosuppressive drugs
CD, Crohn’s disease; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist;
LAMA, long-acting muscarinic agonist; UC, ulcerative colitis.
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bronchiectasis patients commonly encountered with or
without coexisting medical conditions, including but
not limited to asthma, COPD, RA or IBD.
Although there admittedly remain more questions
than answers regarding the best practice for paediatric
and adult bronchiectasis patients with coexisting dis-
ease, current interest, enthusiasm and research funding
are building a platform and creating a space for addi-
tional investigations to advance the science and
address many of the gaps in knowledge to positively
impact patient symptoms, natural course of the disease
process and utilization of healthcare resources.
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